NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other management change announcements
All →Hindustan Bio Sciences Management Change
Hindustan Bio Sciences' Company Secretary and Compliance Officer Shailendra Vyas resigned, effective October 31, 2026. He cited an alternate career opportunity.
Tata Motors Management Change
B S R & Co. LLP resigned as statutory auditor, citing Iveco group alignment. Deloitte Haskins & Sells LLP was appointed to fill the vacancy.
Fortis Healthcare Management Change
Fortis Healthcare's Chief Growth & Innovation Officer, Dr. Ritu Garg, resigned effective close of business on October 31, 2026. The resignation is a senior management personnel change with no monetary impact stated.
Menon Pistons Management Change
Menon Pistons appointed Dr. D.T. Shirke as Non-Executive Independent Director for 36 months from 31 October 2026. Neha Marathe's independent directorship concluded on completion of tenure.
Tribhovandas Bhimji Zaveri Management Change
Tribhovandas Bhimji Zaveri appointed two Managing Directors and a Dy. CEO, and three executive directors resigned. The board reorganisation follows a change in control.
S A Tech Software India Management Change
S A Tech Software India disclosed that Company Secretary and Compliance Officer Arnika Choudhary resigned, effective close of business November 20, 2026. The company is hiring a replacement and will inform the exchanges once filled.